

## XP-002097957

I/1 - (C) WPI / DERWENT  
AN - 89-019644 ç25!  
AP - JP870129551 870526  
PR - JP870129551 870526  
TI - Enteric anticoagulation thrombolytic drug - contains protease with plasminogen activator activity, having low toxicity etc.  
IW - ENTERAL ANTICOAGULANT THROMBOLYTIC DRUG CONTAIN PROTEASE PLASMINOGEN ACTIVATE ACTIVE LOW TOXIC  
PA - (KAOS ) KAO CORP  
PN - JP63295515 A 881201 DW8903 004pp  
ORD - 1988-12-01  
IC - A61K37/54  
FS - CPI  
DC - B04 D16  
AB - J63295515 An anticoagulation thrombolytic drug contains as active ingredient a protease having plasminogen activator activity.  
- The protease having plasminogen activator activity is e.g. prourokinase, tissue plasminogen activator, trypsin, kallikrein, thrombin, bromelain, etc.. Enteric coating is e.g. of ethyl acrylate/methacrylic acid copolymer, hydroxypropyl methyllose cellulose acetate succinate, etc. The dose may be 150,00 to 200,000 urokinase units per day for adult.  
- USE/ADVANTAGE - The protease can be easily administered orally with good effect, and has low toxicity and side effects.